<DOC>
	<DOC>NCT02516319</DOC>
	<brief_summary>The purpose of this study is to 1) determine the feasibility of using Cardiox Liver Function Assessment System (LFA) to measure indocyanine green (ICG) clearance; 2) determine an adequate dose based on LFA technology and 3) determine an adequate time period for LFA determination.</brief_summary>
	<brief_title>Liver Function Assessment - Feasibility and Dosing Study</brief_title>
	<detailed_description>Four cohorts of subjects will be enrolled. The fist two cohorts will receive fixed doses of ICG dye (2.5 mg, 5.0 mg, 7.5 mg, 10.0 mg) followed by 20 minutes of LFT monitoring. The final two cohorts will receive weight based doses of ICG dye (0.1 mg/kg, 0.5 mg/kg) followed by 20 minutes of LFT monitoring. Additionally the final two cohorts will have serial blood draws before the ICG dose and at 5, 10, 15 and 20 minutes post ICG dose.</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<criteria>Male or female subjects, aged 18 to 75 years, inclusive Informed consent documentation understood and signed. Known allergy or sensitivity to the ICG or to iodide contrast dye Pregnant women or those nursing babies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>